State Street’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,044,893
| Closed | -$70.4M | – | 3949 |
|
|
2020
Q3 | $70.4M | Sell |
2,044,893
-1,680,245
| -45% | -$35.8M | ﹤0.01% | 1201 |
|
|
2020
Q2 | $62.2M | Buy |
3,725,138
+1,524,418
| +69% | +$25.9M | ﹤0.01% | 1296 |
|
|
2020
Q1 | $31.7M | Sell |
2,200,720
-1,302
| -0.1% | -$33.3K | ﹤0.01% | 1541 |
|
|
2019
Q4 | $73.7M | Buy |
2,202,022
+484,906
| +28% | +$13.6M | 0.01% | 1252 |
|
|
2019
Q3 | $36M | Sell |
1,717,116
-268,658
| -14% | -$5.48M | ﹤0.01% | 1670 |
|
|
2019
Q2 | $41.3M | Sell |
1,985,774
-106,867
| -5% | -$2.2M | ﹤0.01% | 1601 |
|
|
2019
Q1 | $46.8M | Buy |
2,092,641
+184,547
| +10% | +$4.34M | ﹤0.01% | 1492 |
|
|
2018
Q4 | $45.6M | Buy |
1,908,094
+134,932
| +8% | +$3.49M | ﹤0.01% | 1412 |
|
|
2018
Q3 | $48.4M | Sell |
1,773,162
-597,137
| -25% | -$16.9M | ﹤0.01% | 1558 |
|
|
2018
Q2 | $63.7M | Buy |
2,370,299
+521,617
| +28% | +$16M | 0.01% | 1324 |
|
|
2018
Q1 | $58.8M | Buy |
1,848,682
+626,402
| +51% | +$22M | 0.01% | 1321 |
|
|
2017
Q4 | $46.2M | Buy |
1,222,280
+287,545
| +31% | +$9.28M | ﹤0.01% | 1469 |
|
|
2017
Q3 | $23.2M | Sell |
934,735
-152,585
| -14% | -$3.29M | ﹤0.01% | 1932 |
|
|
2017
Q2 | $22.4M | Buy |
1,087,320
+228,429
| +27% | +$4.36M | ﹤0.01% | 1906 |
|
|
2017
Q1 | $18.7M | Buy |
858,891
+282,744
| +49% | +$5.8M | ﹤0.01% | 1996 |
|
|
2016
Q4 | $11.8M | Buy |
576,147
+193,272
| +50% | +$3.95M | ﹤0.01% | 2247 |
|
|
2016
Q3 | $5.75M | Buy |
382,875
+28,813
| +8% | +$389K | ﹤0.01% | 2479 |
|
|
2016
Q2 | $3.83M | Buy |
354,062
+195,718
| +124% | +$2.66M | ﹤0.01% | 2753 |
|
|
2016
Q1 | $2.15M | Buy |
158,344
+12,596
| +9% | +$197K | ﹤0.01% | 2979 |
|
|
2015
Q4 | $2.69M | Buy |
145,748
+24,211
| +20% | +$448K | ﹤0.01% | 2872 |
|
|
2015
Q3 | $3.08M | Buy |
+121,537
| New | +$2.84M | ﹤0.01% | 2789 |
|
State Street's AIMT Position: Q4 2020 in Review
State Street sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,044,893 shares — an estimated $70.4M sold.
State Street first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $73.7M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- State Street reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- State Street sold 2,044,893 Aimmune Therapeutics shares in Q4 2020, an estimated $70.4M.
- State Street first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- State Street's Aimmune Therapeutics position peaked at $73.7M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on State Street's 13F filing for Q4 2020, filed 16 Feb 2021.